Precertification via phone or fax is required

Precertification of octreotide (Bynfezia Pen, Sandostatin, Sandostatin LAR), lanreotide (Somatuline), pasireotide (Signifor, Signifor LAR) is required for Aetna participating providers and members in applicable plan designs. Precertification may be obtained by phone (866-752-7021) or fax (888-267-3277). Statement of Medical Necessity (SMN) precertification forms (Specialty Pharmacy Precertification) should be used when applicable.

• Call (866) 752-7021 or fax (888) 267-3277 for precertification
• Use Statement of Medical Necessity (SMN) precertification forms where required

Prior authorization for FDA‑approved indications; document indication and disease

Prior authorization (PA) is generally required for agents and uses described in this policy. For FDA‑approved indications (e.g., octreotide for acromegaly, carcinoid syndrome, VIPomas; lanreotide for acromegaly and GEP‑NETs; pasireotide for Cushing’s disease and acromegaly), PA decisions should align with labeled indications and relevant compendia/guidelines. Document the FDA‑approved diagnosis consistent with the drug’s labeling when requesting authorization.

• PA should reflect FDA‑labeled uses and document the indication/diagnosis
• Guidelines and compendia (e.g., NCCN Drug & Biologics Compendium, UpToDate, Endocrine Society) may be used to support PA decisions

Prior authorization likely for off‑label or investigational indications

Prior authorization is likely to be required for off‑label or investigational uses listed in the policy (for example: pasireotide for reduction of post‑operative pancreatic fistula, pasireotide for hepatic cysts, octreotide for lymphorrhea reduction, and many other off‑label indications). Off‑label requests should include supporting clinical rationale and literature or compendia citations; absence of evidence or negative trials may lead to denial.

• Off‑label uses require explicit justification and supporting evidence
• Investigational/experimental indications listed in the policy are not covered

Documentation required for switching to LAR formulations

Specific provider documentation requirements for certain scenarios: for switching from short‑acting to long‑acting (LAR) formulations document prior response and tolerance to subcutaneous octreotide (minimum trial/observation period per product labeling). For depot therapies (e.g., Sandostatin LAR, Signifor LAR, Somatuline Depot) document prior short‑acting trial when indicated and rationale for depot use.

• Document at least 2 weeks of subcutaneous octreotide demonstrating response and tolerability before switching to Sandostatin LAR for acromegaly or carcinoid/VIPomas where labeling indicates
• When switching to LAR formulations, include dosing history, response (GH/IGF‑1, symptom control), and tolerance

Required clinical documentation for chyle leak

Provider requests for management of chyle leak or chylothorax should include documentation that conservative measures were attempted and monitored (e.g., dietary modification, parenteral nutrition, pressure dressings, suction drainage), output measurements, duration, and response. Evidence for post‑surgical chyle leak is heterogeneous; reviewers may request additional data or registry/trial evidence to support therapy.

• Document conservative management attempts (dietary modification, TPN, drainage) and objective leak output (mL/day)
• Provide duration of conservative therapy and timing of octreotide initiation

Prior authorization: LVAD‑related GI bleeding

For LVAD‑related GI bleeding, prior authorization for secondary prophylaxis with octreotide should include documentation of the index GI bleed, prior interventions (endoscopy, transfusions, angiography, embolization), anticoagulation management, and rationale for octreotide as secondary prophylaxis. Evidence is limited to retrospective analyses and case series; PA reviewers may require documentation of recurrent bleeds or failure of conventional measures.

• Document index GI bleeding hospitalization and prior endoscopic/medical interventions
• Document recurrent bleeding episodes and transfusion/endoscopic requirements prior to initiating octreotide for secondary prophylaxis

Evidence limitations — POPF, hepatic cysts, and lymphorrhea not recommended

Evidence limitations and notable negative or neutral trials to note when justifying therapy: pasireotide for prevention of post‑operative pancreatic fistula (POPF) has mixed/negative evidence in some recent studies; pasireotide did not improve cyst reduction in a randomized trial of hepatic cyst aspiration sclerotherapy; randomized data do not support octreotide for lymphorrhea reduction after oncogynecologic lymphadenectomy. Include these findings when assessing requests for these indications.

• Pasireotide for POPF: recent prospective single‑institution data did not show reduced clinically relevant POPF (Young et al 2018)
• Hepatic cysts: RCT (Wijnands et al 2018) showed no benefit of pasireotide adjunct to aspiration sclerotherapy
• Lymphorrhea: RCT evidence does not support octreotide to reduce lymphorrhea after gynecologic lymphadenectomy

Trial documentation (carcinoid syndrome)

Trial documentation examples to support PA for carcinoid syndrome or NET symptom control: provide symptom diaries, rescue short‑acting somatostatin use frequency, objective symptom frequency (diarrhea/flushing), and prior therapy history. For depot agents used in NETs, show prior rescue medication use and symptom burden per trial‑style measures when available.

• Include patient symptom diaries or rescue medication use rates (e.g., days using short‑acting octreotide)
• Provide prior therapy history and objective measures used to demonstrate need for long‑acting therapy

Perioperative use evidence limitations — surgical context required

Perioperative use of pasireotide (to try to reduce postoperative pancreatic fistula) has mixed evidence. If requested, provide surgical context (type of pancreatectomy, duct size, validated risk scores), timing/dosing of pasireotide relative to surgery, and outcomes being targeted (CR‑POPF, drain amylase, length of stay). Reviewers may require higher‑quality trial data or institution‑level protocols to approve perioperative use.

• Document type of pancreatic resection, validated pancreatic fistula risk score, and timing of pasireotide doses (eg, pre‑op and post‑op regimen)
• Provide prior institutional outcomes or protocol if available

This section contains references only; consult cited guidelines and PIs

This section contains references only: compendia (NCCN Drug & Biologics Compendium, UpToDate), prescribing information and peer‑reviewed studies cited in the policy may be consulted to support coverage decisions; however, inclusion in the references does not guarantee coverage. Clinical Policy Bulletins assist benefit administration but do not constitute a guarantee of coverage.

• Refer to cited guidelines, PIs, and compendia when preparing PA documentation
• CPBs are administrative guidance — final coverage depends on plan terms

No explicit step therapy specified here; document prior therapies and sequencing

Operational notes: there is no explicit, uniform step‑therapy algorithm specified in this section for all agents. Specific step‑therapy requirements (for example, trial of short‑acting octreotide before LAR formulations in some labeled uses) are noted in product labeling and should be documented. Pasireotide may be considered after dopamine‑agonist failure for select prolactinomas in case reports/series, but such uses are generally investigational and require strong justification.

• No explicit, universal step‑therapy policy is specified here — follow labeling and local plan requirements
• Document prior dopamine‑agonist therapy and failure if requesting pasireotide for dopamine‑resistant prolactinoma (use generally investigational)